Genasys Inc. Reports Increasing Demand for CONNECT in Wake of 'Signalgate'

SAN DIEGO--(BUSINESS WIRE)-- Genasys Inc. (NASDAQ: GNSS), the global leader In Protective Communications, today announced increasing interest and orders for CONNECT, the company's fully compliant, mission-critical communications platform for government and law enforcement.
'Greater demand for CONNECT has been spurred by the 'Signalgate' controversy, where several members of the federal government used the Signal messaging app for sensitive information sharing,' said Chief Jeff Halstead (Ret.), Genasys Senior Director of Strategic Accounts. 'Since the controversy, we are experiencing increasing demand for CONNECT information, demonstrations and orders from public safety leaders in small towns and large metro areas across the United States.'
To date, strong order demand and contract renewals have grown CONNECT coverage in 41 states and more than 500 agencies, with other states and multiple agencies in deployment trials.
'Many public safety leaders now understand the importance and legal requirements of owning and controlling Interactions when planning and responding to crisis events,' Chief Halstead continued, 'During the last two weeks of national protests, I was contacted by more than a dozen police chiefs thanking me for helping them elevate their communication networks. Through CONNECT, many of them were able to regionally respond to mass protests in just a few minutes.'
CONNECT Platform Advantages
Heavily encrypted messaging from any device to all devices
All messages and data are fully owned and controlled by the agency (Genasys has no access to data, chats, or information)
Fortified Team chats where it is impossible for any person to be mistakenly added
Nothing can be deleted or altered to maintain compliance
Unlimited data sharing, photos, videos and documents
Screenshot protection
No push/share features prevent secure communications from being posted on social media
All persons added to CONNECT are logged and tracked (they can only be added by sending an encrypted invitation directly to them)
All data, chats and attachments are owned by the agency and can be easily reviewed in 30 seconds
Complete transparency and accountability from all elected officials and law enforcement agencies
Full compliance with FOIA, CJIS/FBI, public records retention laws and HIPAA
Encrypted communications platforms like Signal are designed to allow users to hide or delete communications. Using CONNECT, a fully compliant encrypted communications platform specifically created for governmental operations, local, state, and federal governments/agencies can avoid the problems and fallout created by using non-FOIA-compliant consumer apps.
About Genasys Inc.
Genasys Inc. (NASDAQ: GNSS) is the global leader in Protective Communications. Incorporating the most comprehensive portfolio of preparedness, response, and analytics software and systems, as well as the Company's Long Range Acoustic Devices® (LRAD®) the Genasys Protect platform is designed around one premise: ensuring organizations and public safety agencies are 'Ready when it matters™.' Protecting people and saving lives for over 40 years, Genasys covers more than 155 million people in all 50 states and in over 100 countries worldwide. For more information, visit genasys.com.
Forward-Looking Statements
Except for historical information contained herein, the matters discussed are forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these statements. We base these statements on particular assumptions that we have made in light of our industry experience, the stage of product and market development as well as our perception of historical trends, current market conditions, current economic data, expected future developments and other factors that we believe are appropriate under the circumstances. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in any forward-looking statement. The risks and uncertainties in these forward-looking statements include without limitation the business impact of geopolitical conflicts and other causes that may affect our supply chain, and other risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. Risks and uncertainties are identified and discussed in our filings with the Securities and Exchange Commission. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from our current expectations. For more information regarding other potential risks and uncertainties, see the 'Risk Factors' section of the Company's Form 10-K for the fiscal year ended September 30, 2024. Genasys Inc. disclaims any intent or obligation to publicly update or revise forward-looking statements, except as otherwise specifically stated.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

2 hours ago

• Yahoo

Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut

On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering. Housing market weakness triggers Lennar to offer biggest incentives since 2009 The Trump administration is trying to bring back asbestos How one company is revolutionizing the way we use everyday water The diagnostics company's IPO follows the successful debut of fintech companies like Chime Financial and Circle Internet Group, and will test whether investors are ready to embrace biotech companies despite declines in the sector for the last six months. Here's what to know about the listing. Founded in 2008 by David Dean Halbert, the healthcare company utilizes next-generation artificial intelligence (AI) and machine learning for precision medicine. Through molecular analysis, Caris specializes in cancer diagnosis and treatment. According to a recent filing to the Securities and Exchange Commission (SEC), the Irving, Texas-based company currently has over 1,700 employees and over 100 biopharmaceutical partners. The company incurred net losses of $281.9 million and $341.4 million in 2024 and 2023, respectively, on revenue of $412.3 million and $306.1 million. It is expecting additional losses in the future. Caris Life Sciences shares are expected to begin trading on Wednesday, June 18, with the offering expected to run through June 20. Caris Life Sciences will trade its stock under the ticker CAI. CAI shares were priced at $21, above their previously planned range. The IPO price was planned between the $19 and $20 range, up from the previous $16 and $18 planned price. The current pricing would value Caris Life Sciences at around $5.9 billion. CAI will trade its shared on the Nasdaq Global Select Market. Caris Life Sciences's IPO will offer 23,529,412 shares. Founder and CEO Halbert is also set to retain 41.7% of ownership following the IPO. This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio

Business Wire

3 hours ago

• Business Wire

MSCI Announces the Results of the MSCI 2025 Global Market Accessibility Review

NEW YORK--(BUSINESS WIRE)--MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today the results of the MSCI 2025 Global Market Accessibility Review. The detailed report, covering market accessibility assessments for 86 markets, has been made available on Bulgaria is not included in the MSCI 2025 Global Market Accessibility Review report released today. Information for this market will be made available on June 24, 2025, concurrent with the MSCI 2025 Annual Market Classification Review announcement. As a reminder, Bulgaria is under review for potential reclassification from Standalone Market status to Frontier Market status. Key takeaways: There were more improvements than deteriorations in market accessibility ratings. A significant portion of those improvements are attributed to developments in Market Infrastructure across Emerging and Frontier Markets. The MSCI Global Market Accessibility Review aims to assess and track the evolution of accessibility in individual markets, and to inform market authorities about areas that global institutional investors perceive as not meeting international standards and would welcome improvements. Consistent with prior years, the MSCI 2025 Global Market Accessibility Review provides a detailed assessment of market accessibility for each equity market included in the MSCI Indexes and evaluates the following five market accessibility criteria: Openness to foreign ownership Ease of capital inflows/outflows Efficiency of the operational framework Availability of investment instruments Stability of the institutional framework These five criteria reflect areas that international institutional investors generally place strong emphasis on when evaluating investment accessibility of a market, including equal treatment of investors, free flow of capital, cost of investment, unrestrictive use of stock market data, and market-specific risk. MSCI uses 18 distinct accessibility measures to assess these five criteria, described in detail in the MSCI 2025 Global Market Accessibility Review report. Market accessibility, along with economic development and size and liquidity, determine classification of markets into Developed, Emerging, Frontier and Standalone Markets. The classification of markets is a key input in the process of index construction as it determines the composition of the investment opportunity sets to be represented. The results of the MSCI 2025 Annual Market Classification Review will be announced on June 24, 2025. More information on the MSCI Market Classification Framework is available at -Ends- About MSCI MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. The process for submitting a formal index complaint can be found on the index regulation page of MSCI's website at: This document and all of the information contained in it, including without limitation all text, data, graphs, charts (collectively, the 'Information') is the property of MSCI Inc. or its subsidiaries (collectively, 'MSCI'), or MSCI's licensors, direct or indirect suppliers or any third party involved in making or compiling any Information (collectively, with MSCI, the 'Information Providers') and is provided for informational purposes only. The Information may not be modified, reverse-engineered, reproduced or redisseminated in whole or in part without prior written permission from MSCI. All rights in the Information are reserved by MSCI and/or its Information Providers. The Information may not be used to create derivative works or to verify or correct other data or information. For example (but without limitation), the Information may not be used to create indexes, databases, risk models, analytics, software, or in connection with the issuing, offering, sponsoring, managing or marketing of any securities, portfolios, financial products or other investment vehicles utilizing or based on, linked to, tracking or otherwise derived from the Information or any other MSCI data, information, products or services. The user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF THE INFORMATION PROVIDERS MAKES ANY EXPRESS OR IMPLIED WARRANTIES OR REPRESENTATIONS WITH RESPECT TO THE INFORMATION (OR THE RESULTS TO BE OBTAINED BY THE USE THEREOF), AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EACH INFORMATION PROVIDER EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES (INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF ORIGINALITY, ACCURACY, TIMELINESS, NON-INFRINGEMENT, COMPLETENESS, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO ANY OF THE INFORMATION. Without limiting any of the foregoing and to the maximum extent permitted by applicable law, in no event shall any Information Provider have any liability regarding any of the Information for any direct, indirect, special, punitive, consequential (including lost profits) or any other damages even if notified of the possibility of such damages. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited, including without limitation (as applicable), any liability for death or personal injury to the extent that such injury results from the negligence or willful default of itself, its servants, agents or sub-contractors. Information containing any historical information, data or analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. Past performance does not guarantee future results. The Information may include 'Signals,' defined as quantitative attributes or the product of methods or formulas that describe or are derived from calculations using historical data. Neither these Signals nor any description of historical data are intended to provide investment advice or a recommendation to make (or refrain from making) any investment decision or asset allocation and should not be relied upon as such. Signals are inherently backward-looking because of their use of historical data, and they are not intended to predict the future. The relevance, correlations and accuracy of Signals frequently will change materially. The Information should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. All Information is impersonal and not tailored to the needs of any person, entity or group of persons. None of the Information constitutes an offer to sell (or a solicitation of an offer to buy), any security, financial product or other investment vehicle or any trading strategy. It is not possible to invest directly in an index. Exposure to an asset class or trading strategy or other category represented by an index is only available through third party investable instruments (if any) based on that index. MSCI does not issue, sponsor, endorse, market, offer, review or otherwise express any opinion regarding any fund, ETF, derivative or other security, investment, financial product or trading strategy that is based on, linked to or seeks to provide an investment return related to the performance of any MSCI index (collectively, 'Index Linked Investments'). MSCI makes no assurance that any Index Linked Investments will accurately track index performance or provide positive investment returns. MSCI Inc. is not an investment adviser or fiduciary and MSCI makes no representation regarding the advisability of investing in any Index Linked Investments. Index returns do not represent the results of actual trading of investible assets/securities. MSCI maintains and calculates indexes, but does not manage actual assets. The calculation of indexes and index returns may deviate from the stated methodology. Index returns do not reflect payment of any sales charges or fees an investor may pay to purchase the securities underlying the index or Index Linked Investments. The imposition of these fees and charges would cause the performance of an Index Linked Investment to be different than the MSCI index performance. The Information may contain back tested data. Back-tested performance is not actual performance, but is hypothetical. There are frequently material differences between back tested performance results and actual results subsequently achieved by any investment strategy. Constituents of MSCI equity indexes are listed companies, which are included in or excluded from the indexes according to the application of the relevant index methodologies. Accordingly, constituents in MSCI equity indexes may include MSCI Inc., clients of MSCI or suppliers to MSCI. Inclusion of a security within an MSCI index is not a recommendation by MSCI to buy, sell, or hold such security, nor is it considered to be investment advice. Data and information produced by various affiliates of MSCI Inc., including MSCI ESG Research LLC and Barra LLC, may be used in calculating certain MSCI indexes. More information can be found in the relevant index methodologies on MSCI receives compensation in connection with licensing its indexes to third parties. MSCI Inc.'s revenue includes fees based on assets in Index Linked Investments. Information can be found in MSCI Inc.'s company filings on the Investor Relations section of MSCI ESG Research LLC is a Registered Investment Adviser under the Investment Advisers Act of 1940 and a subsidiary of MSCI Inc. Neither MSCI nor any of its products or services recommends, endorses, approves or otherwise expresses any opinion regarding any issuer, securities, financial products or instruments or trading strategies and MSCI's products or services are not a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such, provided that applicable products or services from MSCI ESG Research may constitute investment advice. MSCI ESG Research materials, including materials utilized in any MSCI ESG Indexes or other products, have not been submitted to, nor received approval from, the United States Securities and Exchange Commission or any other regulatory body. MSCI ESG and climate ratings, research and data are produced by MSCI ESG Research LLC, a subsidiary of MSCI Inc. MSCI ESG Indexes, Analytics and Real Estate are products of MSCI Inc. that utilize information from MSCI ESG Research LLC. MSCI Indexes are administered by MSCI Limited (UK) and MSCI Deutschland GmbH. Please note that the issuers mentioned in MSCI ESG Research materials sometimes have commercial relationships with MSCI ESG Research and/or MSCI Inc. (collectively, 'MSCI') and that these relationships create potential conflicts of interest. In some cases, the issuers or their affiliates purchase research or other products or services from one or more MSCI affiliates. In other cases, MSCI ESG Research rates financial products such as mutual funds or ETFs that are managed by MSCI's clients or their affiliates, or are based on MSCI Inc. Indexes. In addition, constituents in MSCI Inc. equity indexes include companies that subscribe to MSCI products or services. In some cases, MSCI clients pay fees based in whole or part on the assets they manage. MSCI ESG Research has taken a number of steps to mitigate potential conflicts of interest and safeguard the integrity and independence of its research and ratings. More information about these conflict mitigation measures is available in our Form ADV, available at Any use of or access to products, services or information of MSCI requires a license from MSCI. MSCI, Barra, RiskMetrics, IPD and other MSCI brands and product names are the trademarks, service marks, or registered trademarks of MSCI or its subsidiaries in the United States and other jurisdictions. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P Dow Jones Indices. 'Global Industry Classification Standard (GICS)' is a service mark of MSCI and S&P Dow Jones Indices. MIFID2/MIFIR notice: MSCI ESG Research LLC does not distribute or act as an intermediary for financial instruments or structured deposits, nor does it deal on its own account, provide execution services for others or manage client accounts. No MSCI ESG Research product or service supports, promotes or is intended to support or promote any such activity. MSCI ESG Research is an independent provider of ESG data.

Yahoo

4 hours ago

• Yahoo

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. It could soon have company, however, as others strive to develop their own treatments. Viking Therapeutics and Altimmune have exciting GLP-1 products entering phase 3 trials. 10 stocks we like better than Viking Therapeutics › Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients with diabetes and weight loss. In five years, the stock has soared by close to 480%, which would have turned a $20,000 investment into approximately $116,000. The GLP-1 market is still in its early growth stages, and there's plenty of room for more companies to make names for themselves. While Eli Lilly is a safe bet to invest in right now, if you want a position in stocks that may have considerably more upside in the GLP-1 market, there are two names you should take a closer look at today: Viking Therapeutics (NASDAQ: VKTX) and Altimmune (NASDAQ: ALT). The big excitement surrounding Viking is it has a GLP-1 treatment that could be a viable option for weight loss. VK2735 isn't an approved treatment yet, but it has been showing encouraging results in early-stage trials. In data released last year, a phase 2 trial showed that the drug was able to help patients lose up to 14.7% of their body weight after 13 weeks, without signs of any plateau, suggesting further weight loss could be possible. Phase 3 trials are set to begin this year. Meanwhile, Viking is also working on an oral version of the treatment, which is currently in phase 2 trials. The phase 1 data from that looked solid, with trial participants losing up to 8.2% of their body weight after 28 days. The risk with Viking is that it isn't generating revenue today, and it doesn't have any approved products. It has incurred a net loss totaling $128 million over the trailing 12 months, and there's a real possibility that those losses could deepen as it spends more on clinical trials. If VK2735 isn't successful and doesn't obtain approval from regulators, the stock could nosedive, which is the biggest concern for investors. Investors have largely looked past Viking this year, as the healthcare stock is down 35% (as of June 13), pulling its market cap down to less than $3 billion. However, if there's encouraging clinical data to come out in the future, that could trigger a rally in Viking's stock. This is a company that has a lot of upside, and if you're OK with taking on some risk, this may be a good stock to invest in a modest amount of money into. Altimmune is similar to Viking, but it's much smaller in market capitalization, worth less than $600 million. It hasn't been as popular of an option for investors, but it's an investment that may have even greater upside, given its more modest valuation. It also has a promising GLP-1 product that investors are bullish on: pemvidutide. In a phase 2 trial, participants lost an average of 15.6% of their body weight after a period of 48 weeks on the highest dosage (2.4 mg). The company doesn't have an oral version in development, but it is also testing pemvidutide as a treatment for other conditions, including metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol liver disease. Altimmune generates limited revenue (primarily coming from grants and contracts), and until and unless it obtains approval for pemvidutide, that's likely to stay this way. Over the past four quarters, its losses have totaled $90 million, and it has burned through more than $80 million just from its day-to-day operating activities. With around $150 million in cash and short-term investments, it's adequately funded, but there is high likelihood of share offerings being necessary in the future, and dilution is a real concern for investors. If pemvidutide becomes a success, Altimmune could easily double or triple in value and potentially be an acquisition target for a larger healthcare company seeking opportunities in GLP-1. There's risk with Altimmune, but there could also be tremendous upside. If you can stomach the uncertainty, you may want to consider taking a chance on the stock. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data